ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Ethnopharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1496232
Cannabis Tolerance Reduces Symptom Relief
Provisionally accepted- 1University of New Mexico, Albuquerque, United States
- 2Releaf app, Washington, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objectives: We measure for the first time how tolerance from repeated consumption of medical cannabis affects acute symptom management.Methods: Using the Releaf App, medical cannabis patients recorded their symptoms, product type, cannabis consumption method, major cannabinoid levels, dosing patterns, and real-time symptom intensity levels prior to and following each cannabis administration session, as well as any side effects from usage. The sample consists of the first ten cannabis self-administration sessions recorded by 16,395 medical cannabis patients between 06/05/2016 and 09/19/22, yielding a sample of 120,691 symptom-specific treatment-level observations, recorded during 42,005 sessions. This study uses fixed effects least-squares regression analyses to analyze the effects of the session count on symptom relief.Results: On average, people experienced a 0.5% decrease in symptom relief with each subsequent session (p<0.001). Combustible products offered more therapeutic relief than vaping, eating or drinking; higher doses offered greater relief; and the reduction in symptom relief with subsequent usage was similar whether patients were treating pain, depression, or anxiety. Cannabis products' THC levels were positively associated with symptom relief; however, patients showed no changes in the THC levels of products with subsequent consumption. Patients increased the dose consumed as they completed more sessions. The results are robust to alternative treatment measures, including days since the first session was recorded. Subsample regressions indicate that experienced users drive most of the effects. Analyses assessing side effects show that factors, such as THC and dose, that increased symptom relief also increased side effects experienced.Conclusions and Implications: The findings suggest the majority of patients experience decreased symptom relief after repeated use of medical cannabis, counterbalanced by improvements in negative side effects. Of direct clinical relevance, THC levels and the dose can be adjusted to customize medical cannabis patient treatment, increase medication compliance, and improve treatment outcomes.
Keywords: tolerance, Cannabis, marijuana, Addiction, Cannabidiol, Tetrahydrocannabinol, cannabis chemovars, Complementary medicine
Received: 13 Sep 2024; Accepted: 21 May 2025.
Copyright: © 2025 Vigil, Stith, Li, Brockelman, Keeling and Hall. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Jacob Miguel Vigil, University of New Mexico, Albuquerque, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.